This forecast represents the prevalence of diabtes among the total population of the United States in 2025, sorted by characteristic. In 2025, the diabetes prevalence for the United States is expected to be 14.9 percent.

This forecast represents the total number of people in the United States in 2025 with diabetes, sorted by characteristic. In 2025, some 53.1 million people are expected to have diabetes in the United States.

Diabetes prevalence (% of population ages 20 to 79) in Spain was reported at 10.3 % in 2021, according to the World Bank collection of development indicators, compiled from officially recognized sources. Spain - Diabetes prevalence (% of population ages 20 to 79) - actual values, historical data, forecasts and projections were sourced from the World Bank on March of 2025.

Diabetes prevalence (% of population ages 20 to 79) in Ireland was reported at 3 % in 2021, according to the World Bank collection of development indicators, compiled from officially recognized sources. Ireland - Diabetes prevalence (% of population ages 20 to 79) - actual values, historical data, forecasts and projections were sourced from the World Bank on March of 2025.

Snapshot img

Type 2 Diabetes Market Size 2025-2029

The type 2 diabetes market size is forecast to increase by USD 53.8 billion at a CAGR of 12.2% between 2024 and 2029.

The market is experiencing significant growth due to several key factors. The rising prevalence of diabetes, driven by unhealthy lifestyles and an aging population, is a major growth driver. Additionally, the low diagnosis rate presents an opportunity for market expansion. It is administered via different routes, including subcutaneous injection, insulin pumps, and insulin pens. According to the American Diabetes Association, approximately 26.8 million people in the United States have diabetes, and 7.3 million are undiagnosed. With increasing awareness and advancements in diagnostic tools, this number is expected to increase. These include continuous glucose monitoring systems, closed-loop insulin delivery systems, and non-pharmacological interventions such as diet and exercise. Furthermore, the growing burden of diabetes on healthcare systems and the need for effective management solutions are creating new opportunities for market participants. Overall, the market is poised for growth in the coming years, driven by these key trends and challenges.

What will be the Size of the Type 2 Diabetes Market During the Forecast Period?

Request Free Sample

The market encompasses a range of therapeutic compounds designed to manage and mitigate the effects of this chronic condition. With a global prevalence estimated to affect over 463 million people, primarily adolescents and young adults, the market exhibits significant growth due to the increasing burden of cardiovascular diseases, renal problems, and neurological complications associated with hyperglycemia. These complications include heart diseases, damage to the kidneys, and eye disorders, among others. Insulin and non-insulin medications, such as Jardiance, Tanzeum, and Trulicity, are commonly used to regulate blood sugar levels and alleviate symptoms like increased thirst, urination, fatigue, blurred vision, slow-healing wounds, and infections. Additionally, patients may experience tingling, numbness in feet and hands, and other neurological issues. Pharmaceutical companies continue to invest in research and development to address the unmet needs of this patient population and improve overall quality of life.

How is this Type 2 Diabetes Industry segmented and which is the largest segment?

The type 2 diabetes industry research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in 'USD billion' for the period 2025-2029, as well as historical data from 2019-2023 for the following segments.

Drug Class

  Insulin
  DPP-4 inhibitor
  GLP-1 receptor agonists
  SGLT-2 inhibitors
  Others


Distribution Channel

  Retail pharmacies
  Hospital pharmacies
  Online pharmacies


Delivery Mode

  Oral
  Injectable
  Continuous glucose monitoring (CGM)


Geography

  North America

    Canada
    US


  Europe

    Germany
    UK
    France
    Italy


  Asia

    China
    India
    Japan
    South Korea


  Rest of World (ROW)

By Drug Class Insights

The insulin segment is estimated to witness significant growth during the forecast period.

Type 2 diabetes is a chronic metabolic disorder characterized by insulin resistance and high blood glucose levels. This condition affects adolescents, teenagers, and young adults, leading to increased thirst, urination, fatigue, blurred vision, slow-healing wounds, infections, tingling, numbness in feet and hands, yeast infections, darkened skin areas, and neurological problems. Over time, high blood glucose levels can lead to cardiovascular diseases, renal problems, and damage to the eyes. Insulin, a peptide hormone, plays a crucial role in regulating blood glucose levels. It interacts with insulin receptors on cell surfaces, facilitating the absorption of glucose into the cells. Insulin deficiency or insulin resistance leads to hyperglycemia, which can result in complications. The market for therapeutic compounds to manage Type 2 diabetes includes various drug classes such as insulin, thiazolidinediones, PPAR receptors agonists, Dipeptidyl Peptidase-4 Inhibitors, Alpha-Glucosidase Inhibitors, Sulfonylureas, Secretagogues, Biguanides, and others.

Moreover, these medications help improve glycemic control, reduce cardiovascular risk, and avoid hypoglycemia. Insulin is available in various forms, including human insulin, analog insulins, and inhaled insulin. Retail pharmacies and online pharmacies offer convenience for patients to access insulin and other diabetes medications. The market for Type 2 diabetes medications is expected to grow significantly due to the increasing prevalence of the disease and the need for effective disease management. Emerging economies are expected to offer significant growth opportunities due to increasin

This forecast represents the number of people in the United States in 2025 with prediabetes, sorted by characteristic. In 2025, approximately 91 million people in the U.S. are expected to have prediabetes.

This statistic shows the number of diagnosed prevalent cases of type 2 diabetes worldwide in 2015 and a forecast for 2025, by country. In 2015, there were over 25 million cases of type 2 diabetes in the U.S. This number is expected to grow to almost 38 million by the year 2025.

Diabetes prevalence (% of population ages 20 to 79) in Togo was reported at 2.1 % in 2021, according to the World Bank collection of development indicators, compiled from officially recognized sources. Togo - Diabetes prevalence (% of population ages 20 to 79) - actual values, historical data, forecasts and projections were sourced from the World Bank on March of 2025.

Diabetes prevalence (% of population ages 20 to 79) in Sweden was reported at 5 % in 2021, according to the World Bank collection of development indicators, compiled from officially recognized sources. Sweden - Diabetes prevalence (% of population ages 20 to 79) - actual values, historical data, forecasts and projections were sourced from the World Bank on March of 2025.

Diabetes prevalence (% of population ages 20 to 79) in Bolivia was reported at 5.5 % in 2021, according to the World Bank collection of development indicators, compiled from officially recognized sources. Bolivia - Diabetes prevalence (% of population ages 20 to 79) - actual values, historical data, forecasts and projections were sourced from the World Bank on March of 2025.

Diabetes prevalence (% of population ages 20 to 79) in Liberia was reported at 2.1 % in 2021, according to the World Bank collection of development indicators, compiled from officially recognized sources. Liberia - Diabetes prevalence (% of population ages 20 to 79) - actual values, historical data, forecasts and projections were sourced from the World Bank on March of 2025.

This forecast represents the number of people in the United States in 2025 with diagnosed and undiagnosed diabetes, divided by characteristic. In 2025, some 38.7 million people are expected to be diagnosed with diabetes and some 14.4 million people are expected to live with undiagnosed diabetes.

The global market for Diabetes Mellitus Treatment is experiencing steady growth, projected to reach a substantial size. While the exact 2025 market size is not provided, considering a 5% CAGR and a reasonable starting point based on industry reports, we can estimate the market to be valued at approximately $800 million in 2025. This positive growth trajectory is expected to continue throughout the forecast period (2025-2033), driven by several key factors. The increasing prevalence of both Type 1 and Type 2 diabetes, particularly in aging populations across North America, Europe, and Asia-Pacific, is a major catalyst. Furthermore, advancements in treatment modalities, including the development of more effective and convenient insulin delivery systems and the emergence of novel therapeutic approaches, are fueling market expansion. The market is segmented by diabetes type (Type 1 and Type 2) and patient demographics (children, adults, and the elderly), allowing for targeted treatment strategies and market penetration. Major players like Novo Nordisk, Sanofi, and others are actively investing in research and development, contributing to the growth and innovation within the sector. However, the market faces certain challenges. High treatment costs remain a significant barrier to access, particularly in developing regions. Furthermore, the long-term nature of diabetes management presents adherence challenges. Despite these constraints, the overall market outlook for Diabetes Mellitus Treatment remains optimistic, driven by the persistent rise in diabetes prevalence and ongoing therapeutic advancements. The market is anticipated to continue expanding at a considerable pace in the coming years, offering lucrative opportunities for pharmaceutical companies and healthcare providers alike.

The 7 major gestational diabetes markets are expected to exhibit a CAGR of 4.85% during 2025-2035.

The global diabetic food market size reached USD 12.9 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 23.3 Billion by 2033, exhibiting a growth rate (CAGR) of 6.47% during 2025-2033. The market is growing rapidly driven by increasing prevalence of diabetes, heightened awareness about health and nutrition among consumers, recent advancements in food technologies, imposition of various initiatives and regulations by governments, and changing lifestyle patterns of consumers.

Market Overview:

The 7 major prediabetes markets reached a value of US$ 23.8 Billion in 2024. Looking forward, IMARC Group expects the 7MM to reach US$ 48.7 Billion by 2035, exhibiting a growth rate (CAGR) of 6.72% during 2025-2035.

The prediabetes market has been comprehensively analyzed in IMARC's new report titled "Prediabetes Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2025-2035". Prediabetes is a medical condition characterized by higher-than-normal blood sugar levels that are not yet high enough to be classified as type 2 diabetes. It is considered an intermediate stage between normal blood sugar levels and a diabetes diagnosis. In this disease, the body's cells become less responsive to the action of insulin, a hormone produced by the pancreas that helps to regulate blood sugar levels. There may be no obvious signs or symptoms of the illness, but some individuals suffering from prediabetes may experience increased thirst, frequent urination, heightened hunger, fatigue, blurred vision, changes in weight, slow-healing sores, numbness or tingling in the hands or feet, etc. The diagnosis of this ailment is typically made by a review of the patient's medical history, clinical features, and laboratory studies. The healthcare provider may also perform several blood workups, such as a fasting plasma glucose test, an oral glucose tolerance test, a glycated hemoglobin (A1C) test, etc., to measure the amount of sugar in the bloodstream and confirm a diagnosis among patients.

https://www.imarcgroup.com/CKEditor/bcd48b05-3e06-412c-b3a4-3b9d06cc106eprediabetes-market-report-(1).webp" style="height:450px; width:800px" />

The rising cases of genetic conditions, which can lead to insulin resistance and impaired glucose metabolism due to mutations in specific genes, are primarily driving the prediabetes market. Furthermore, the growing prevalence of several associated risk factors, such as a sedentary lifestyle, obesity, consumption of an unhealthy diet, etc., is also propelling the market growth. In addition to this, the escalating utilization of anti-diabetic medications, like metformin, to lower the amount of sugar produced and absorbed by the body, thereby preventing disease progression, is creating a positive outlook for the market. Moreover, the inflating adoption of continuous glucose monitoring (CGM) devices, which offer immediate feedback on glucose levels, including alerts for high or low blood sugar levels, and enable patients to take prompt action for the management of the ailment, is also bolstering the market growth. Apart from this, the emerging popularity of glucagon-like peptide-1 receptor agonists for treating the condition by increasing insulin secretion, promoting weight loss, and enhancing the quality of life is expected to drive the prediabetes market in the coming years.

IMARC Group's new report provides an exhaustive analysis of the prediabetes market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for prediabetes and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the prediabetes market in any manner.

Time Period of the Study

• Base Year: 2024
• Historical Period: 2019-2024
• Market Forecast: 2025-2035

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
  

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the prediabetes market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the prediabetes market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current prediabetes marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
  

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
  

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the prediabetes market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2024 and how are they expected to perform till 2035?
• What was the country-wise size of the prediabetes market across the seven major markets in 2024 and what will it look like in 2035?
• What is the growth rate of the prediabetes market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?
  

Epidemiology Insights

• What is the number of prevalent cases (2019-2035) of prediabetes across the seven major markets?
• What is the number of prevalent cases (2019-2035) of prediabetes by age across the seven major markets?
• What is the number of prevalent cases (2019-2035) of prediabetes by gender across the seven major markets?
• How many

According to cognitive market research, the global diabetic neuropathy market size was valued at USD xx billion in 2024 and is expected to reach USD xx billion at a CAGR of xx% during the forecast period.

The global market for diabetic neuropathy is being driven, among other things, by rising market developments and rising diabetes cases. 
The increasing public awareness of healthcare facilities and preventive treatments, which are expanding to accommodate more services, is also contributing to the development of the market.
Some of the obstacles to market expansion include the growing cost of diabetic neuropathy medications, the growing availability of alternative medications, and other factors.
The American regional market is growing at a CAGR of xx%. The high rate of diabetes in the area is responsible for market dominance.
Major market participants who are essential in determining consumer preferences and market dynamics have a major impact on the diabetic neuropathy market.

Market Dynamics of the Diabetic Neuropathy Market

Key Drivers of the Diabetic Neuropathy Market

Growing awareness among people and increasing dependence on diabetes control measures to boost market growth

With chronic diabetes becoming more commonplace worldwide, there is a sizable patient base. Thus, whether or not someone they know has experienced it, people all over the world have gradually become more aware of the same. In addition, a lot of efforts have been made to raise awareness of these complications associated with diabetes, which is driving demand for care and treatment services. The increasing public awareness of healthcare facilities and preventive treatments, which are expanding to accommodate more services, is also contributing to the development of the market. WHO and IDF are working together to prevent & control diabetes and ensure good quality of life for people worldwide. • For instance, the WHO Diabetes Program is aimed at preventing type 2 diabetes, reducing complications, and improving the quality of life for people with diabetes. (Source:https://www.who.int/initiatives/the-who-global-diabetes-compact)

Rapidly increasing chronic diabetic patients globally significantly drive the market

One of the most common illnesses with serious negative effects on human health is diabetes. These chronic lifestyle diseases have a wide geographic distribution and have been linked to people from all socioeconomic backgrounds. During the projection period, the global demand for diabetic neuropathy would grow at a slower rate due to the rising prevalence of diabetes. In addition, several conditions including obesity, heart disease, diabetic neuropathy, and other problems with sugar are believed to be contributing to the market's growth. Growing urbanization, which encourages sedentary lifestyles like consuming carbohydrates and engaging in little physical activity, has an impact on the market's growth as well. • For instance, Diabetes currently has a global prevalence rate of 6.1%, ranking it among the top ten leading causes of death and disability. (Source:https://www.who.int/news-room/fact-sheets/detail/the-top-10-causes-of-death)

Restraints of the Diabetic Neuropathy Market

Highly-priced medications and alternative treatments hinder market growth.

Some of the obstacles to market expansion include the growing cost of diabetic neuropathy medications, the growing availability of alternative medications, and other factors. The availability of alternative therapies like physiotherapy and radiotherapy, which are regarded as more comfortable and may offer patients satisfactory clinical results, is one factor limiting the market's potential. Given the continued global increase in the prevalence of both diabetes and related neuropathy, the degree of regional expansion in the treatment of diabetic neuropathy can be regarded as moderate. Tight regulations, product recalls, delays in Food and Drug Administration clearances, and other issues of a similar nature could also impede the growth of this market. • For instance, duloxetine can range from $9.00 to $54.31. Thus, the high cost of drugs used for the treatment of diabetic peripheral neuropathy may hinder the growth of the market during the forecast period. (Source:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC...

According to a survey conducted between 2019 and 2021 in India, about four percent each among men and women, aged 35 to 49 years reported having diabetes. During the same time period, Indians between 15 and 19 years old had the lowest prevalence of diabetes.

According to Cognitive Market Research, the global glucose monitoring devices market was valued at USD XX in 2023 and it is expected to grow at a CAGR of XX% from 2024 to 2029.

The global software engineering market will grow significantly by XX% CAGR between 2024 to 2029.
Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market.
The report includes an analysis of the regional as well as market trends, key players, application areas, and market growth strategies.
Detailed analysis of Market Drivers, Restraints and Opportunities
North America dominated the market and accounted for the highest revenue of XX% in 2023 and it is projected that it will grow at a CAGR of XX% in the future.
The report consists size of the market.

Market Dynamics of Glucose Monitoring Devices

Key Drivers

Improving device synchronized data and accuracy for monitoring the glucose level drives the glucose monitoring device market

One of the most important aspects of the monitoring device is the accuracy with which it measures glucose levels. Accurate glucose monitoring is critical for successful diabetes management because it directly influences treatment decisions and patient outcomes. Several companies have developed advanced versions of conventional blood glucose monitors that are portable and minimally invasive. Many next-generation solutions include connectivity features that allow patients' health data to be captured and shared with medical professionals upon request. Companies are doing continuous innovation on the product for giving exact data to the customers. For Instance, in June 2024 Roche Holding AG receives CE mark for its AI enabled continuous glucose monitoring solution offering critical predictions to people living with 1 and type 2 diabetes n flexible insulin therapy. (source https://www.stocktitan.net/news/RHHBY/roche-receives-ce-mark-for-its-ai-enabled-continuous-glucose-i6j95ac2d9ie.html) Modern devices can now provide reliable and consistent readings, lowering the risk of complications caused by incorrect glucose measurements. Exact readings give patients more control over their blood glucose levels, resulting in fewer episodes of hyperglycemia or hypoglycemia. The development of continuous glucose monitoring (CGM) systems marks a significant technological advancement. Furthermore, accurate glucose monitoring devices are critical for healthcare providers because they allow for precise monitoring and individualized treatment plans. This can lead to more efficient resource utilization and improved patient outcomes, thereby driving market growth. As technology advances, glucose monitoring devices' accuracy is expected to improve even more, solidifying their role in effective diabetes management and expanding their global adoption.

Rising number of diabetes patients will further boost the glucose monitoring devices market

The growing incidence of diabetes among populations in both developed and undeveloped countries is leading to a large patient pool worldwide requiring blood monitoring, leading to an increase in demand for these devices among the patient population. Several factors, including rapid urbanization and the rising shift toward a sedentary lifestyle, in emerging and developed countries are primarily responsible for the growing prevalence of diabetes. For Instance, according to International Diabetes Federation (IDF) in 2021, it was estimated that around 537 million adults had diabetes, and China, India, U.S.A., Brazil and Mexico accounted for an estimated 51.6% of the global diabetes population in 2021. (source https://diabetesatlas.org/#:~:text=Diabetes%20around%20the%20world%20in%202021%3A,%2D%20and%20middle%2Dincome%20countries) A significant increase has been observed in the number of patients suffering from type-1 or insulin-dependent type 2 diabetes, which has been instrumental in surging the uptake of glucose monitoring systems globally. Thus, the presence of a large diabetic population with insulin-dependent diabetes, new product introductions by market players, and favorable reimbursement are driving demand and adoption of glucose monitoring devices

Restraints

The high cost of devices hinders the market growth

The glucose monitoring device is expensive and can be painful. Diabetes care devices do not always produce accurate results. Many hospitals and health...

The India diabetes market size was valued at INR 316.00 Billion in 2024, driven by high prevalence of diabetes cases across the region. The market is expected to grow at a CAGR of 16.00% during the forecast period of 2025-2034, to reach INR 1394.01 Billion by 2034.